The Recall Desk
LowFDA (Drugs)·D-0180-2021·Announced 2021-01-06

Strides Pharma Recalls Tacrolimus Capsules for Failed Moisture Limits

Strides Pharma Inc. is recalling 960 bottles of 1mg Tacrolimus capsules due to failed moisture limits. The recall is limited to Pennsylvania.

What this means for you

Cosmetic or documentation issue. No expected health impact, but the manufacturer is correcting the affected products.

Our severity reasoning: The agency classified this as an FDA Class III recall, which by definition is unlikely to cause adverse health consequences, fitting the 'Low' severity criteria for documentation or minor quality issues.

Plain-English summary

Strides Pharma Inc. is recalling 960 bottles of TACROLIMUS CAPSULES, USP 1mg (NDC 64380-721-06). The product is manufactured by Strides Pharma Science Ltd. in Bengaluru, India, and distributed by Strides Pharma Inc. in East Brunswick, NJ. The specific lot affected is 7242728A, with a June 2023 expiration date.

The recall was initiated because the product failed moisture limits. This is a Class III recall, which indicates that the violation is not likely to cause adverse health consequences. The distribution was limited to Pennsylvania (PA).

Consumers who have this specific lot of medication should stop using it and contact their pharmacist or healthcare provider for guidance on replacement or further instructions.

The recalled product

Product
TACROLIMUS (TACROLIMUS)
Brand
TACROLIMUS
Affected units
960

Is your product affected?

Check your packaging against the codes below. If any of them match, the product is part of this recall.

Lot numbers (2)

  • Lot 7242728A
  • June 2023

UPCs (3)

  • 0364380721062
  • 0364380720065
  • 0364380722069

Distribution

Distributed in 1 state: